Mesoblast (MEOBF) EBITDA (2014 - 2023)

Mesoblast has disclosed EBITDA across 10 years of filings, most recently posting -$25.7 million for Q2 2023.

• In Q2 2023, EBITDA fell 116.32% year-over-year to -$25.7 million; the TTM figure through Jun 2023 stood at -$101.5 million (down 235.97% YoY), while the FY2026 annual figure was $163.9 million, up 301.88% from the prior year.
• EBITDA came in at -$25.7 million for Q2 2023 at Mesoblast, down from -$23.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $168.4 million in Q2 2021 to a low of -$61.3 million in Q1 2020.
• Average EBITDA over 5 years is -$6.7 million, with a median of -$26.7 million recorded in 2020.
• Year-over-year, EBITDA jumped 52.77% in 2019 and tumbled 159.15% in 2020.
• Over 5 years, EBITDA stood at -$40.7 million in 2019, then surged by 34.4% to -$26.7 million in 2020, then decreased by 17.71% to -$31.4 million in 2021, then increased by 2.1% to -$30.7 million in 2022, then climbed by 16.3% to -$25.7 million in 2023.
• Per Business Quant data, the three most recent EBITDA figures were -$25.7 million in Q2 2023, -$23.6 million in Q1 2023, and -$30.7 million in Q4 2022.